Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report issued on Thursday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a report on Monday, March 10th.

Aethlon Medical Price Performance

Shares of Aethlon Medical stock opened at $0.43 on Thursday. The stock has a market cap of $6.22 million, a P/E ratio of -0.27 and a beta of 1.80. The stock’s 50 day simple moving average is $0.58 and its 200-day simple moving average is $0.50. Aethlon Medical has a 1-year low of $0.24 and a 1-year high of $1.85.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.09. As a group, research analysts expect that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Institutional Trading of Aethlon Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AEMD. Allegiance Financial Group Advisory Services LLC purchased a new stake in Aethlon Medical in the fourth quarter valued at approximately $26,000. Virtu Financial LLC purchased a new stake in Aethlon Medical in the fourth quarter valued at approximately $81,000. Renaissance Technologies LLC purchased a new stake in Aethlon Medical in the fourth quarter valued at approximately $25,000. Sassicaia Capital Advisers LLC purchased a new stake in Aethlon Medical in the fourth quarter valued at approximately $31,000. Finally, Boothbay Fund Management LLC purchased a new stake in Aethlon Medical in the fourth quarter valued at approximately $186,000. Hedge funds and other institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.